Genzyme names leaders of MS, rare diseases units

CAMBRIDGE, Mass. — Genzyme has named leaders of two units that are part of the core focus of the drug maker's business.

Bill Sibold, former chief commercial officer at Avanir Pharmaceuticals, was appointed to serve as head of the multiple sclerosis business, while Rogério Vivaldi, who most recently served as president of Genzyme’s renal and endocrinology business, now is the head of the rare diseases business.

Both Sibold and Vivaldi will report to Genzyme president and CEO David Meeker, who recently became part of the company's executive team.

“These appointments are a critical step in launching the new Genzyme,” Meeker said. “Bill and Rogério are dynamic leaders with the experience, energy, vision and commitment to patients needed to move us forward.”

Genzyme is a Sanofi company.

Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Login or Register to post a comment.